Yaman Walid Kassab
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yaman Walid Kassab has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Amra Salahuddin
Jinnah Sindh Medical University, Karachi, Pakistan
4 shared publications- Muhammad Shahid Iqbal
Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
4 shared publications Muhammad Umer Abdul Moiz
Jinnah Medical and Dental College, Karachi, Pakistan
4 shared publications- Abdul Haseeb
Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
3 shared publications Abdullah Ehsan
Jinnah Medical and Dental College, Karachi, Pakistan
3 shared publications- Ahmed Alaa Al-Temimi
Clinical Pharmacy Department, College of Pharmacy, Al-Bayan University, Baghdad, Iraq
3 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Long-term effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A retrospective cohort study from Oman
Objectives: Sacubitril/valsartan has shown benefits in managing heart failure with reduced ejection fraction (HFrEF). However, more data on its effectiveness and safety in diverse populations is needed. This study evaluated its long-term effects on echocardiographic and clinical parameters of heart function and reverse cardiac remodeling in Omani patients with HFrEF, with an emphasis on gender-related differences. Methods: This retrospective cohort study was conducted at a tertiary hospital in Oman from January 2018 to December 2023. Data were collected through retrospective chart reviews and follow-up assessments conducted 12 months after initial assessment. Results: Among the patients, 72.5% were male, with a mean age of 60.1 ± 11.4 years. Significant improvements were observed in systolic blood pressure (137.7 ± 19.38 to 131.59 ± 19.23 mmHg, p = 0.013), diastolic blood pressure (80 to 74.5 mmHg, p < 0.001), heart failure class (2 to 1, p < 0.001), left ventricular ejection fraction (31% to 37%, p < 0.001), end-systolic volume (112.69 ± 37.78 mL, p = 0.011), and left atrium diameter (4.1 to 4 cm, p = 0.002). Female patients experienced greater treatment benefits. No association was found between reverse cardiac remodeling and gender or comorbidities. Conclusion: Sacubitril/valsartan demonstrated significant benefits in managing HFrEF in Omani patients. Gender differences in response highlight the need for personalized treatment strategies.
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Open AccessLong-term effects of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A retrospective cohort study from Oman
Objectives: Sacubitril/valsartan has shown benefits in managing heart failure with reduced ejection fraction (HFrEF). However, more data on its effectiveness and safety in diverse populations is needed. This study evaluated its long-term effects on echocardiographic and clinical parameters of heart function and reverse cardiac remodeling in Omani patients with HFrEF, with an emphasis on gender-related differences. Methods: This retrospective cohort study was conducted at a tertiary hospital in Oman from January 2018 to December 2023. Data were collected through retrospective chart reviews and follow-up assessments conducted 12 months after initial assessment. Results: Among the patients, 72.5% were male, with a mean age of 60.1 ± 11.4 years. Significant improvements were observed in systolic blood pressure (137.7 ± 19.38 to 131.59 ± 19.23 mmHg, p = 0.013), diastolic blood pressure (80 to 74.5 mmHg, p < 0.001), heart failure class (2 to 1, p < 0.001), left ventricular ejection fraction (31% to 37%, p < 0.001), end-systolic volume (112.69 ± 37.78 mL, p = 0.011), and left atrium diameter (4.1 to 4 cm, p = 0.002). Female patients experienced greater treatment benefits. No association was found between reverse cardiac remodeling and gender or comorbidities. Conclusion: Sacubitril/valsartan demonstrated significant benefits in managing HFrEF in Omani patients. Gender differences in response highlight the need for personalized treatment strategies.
- Open Access
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Effects of heavy metal toxicity on biochemical parameters of fresh water fish, Oreochromis mossambicus (Tilapia)
Aquatic resources are increasingly impacted by various pollutants, with water bodies being particularly vulnerable to industrial pollution due to the direct discharge of effluents. This study focuses on the toxicity of heavy metals in fish. Fish are considered ecological indicators, and the sub-lethal effects of poisoning can be assessed through histopathological responses. In this study, fish were evaluated for changes in enzyme activity, including lactate dehydrogenase (LDH), acid phosphatase (ACP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), as well as the formation of biomolecules such as carbohydrates, proteins, and lipids. The test species used was the freshwater fish Oreochromis mossambicus (Tilapia). A sub-lethal concentration of lead acetate (2 mg/L) was administered as a single dose. After 24 hours and 48 hours of exposure, the fish were sacrificed, and tissues such as the gills, liver, and muscles were dissected for enzyme assays. Statistical analysis revealed significant alterations in enzyme activity for ACP, ALT, AST, and ALP, as well as in forming biomolecules. A decrease in enzyme activity was observed when compared to the control group.
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Open AccessEffects of heavy metal toxicity on biochemical parameters of fresh water fish, Oreochromis mossambicus (Tilapia)
Aquatic resources are increasingly impacted by various pollutants, with water bodies being particularly vulnerable to industrial pollution due to the direct discharge of effluents. This study focuses on the toxicity of heavy metals in fish. Fish are considered ecological indicators, and the sub-lethal effects of poisoning can be assessed through histopathological responses. In this study, fish were evaluated for changes in enzyme activity, including lactate dehydrogenase (LDH), acid phosphatase (ACP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP), as well as the formation of biomolecules such as carbohydrates, proteins, and lipids. The test species used was the freshwater fish Oreochromis mossambicus (Tilapia). A sub-lethal concentration of lead acetate (2 mg/L) was administered as a single dose. After 24 hours and 48 hours of exposure, the fish were sacrificed, and tissues such as the gills, liver, and muscles were dissected for enzyme assays. Statistical analysis revealed significant alterations in enzyme activity for ACP, ALT, AST, and ALP, as well as in forming biomolecules. A decrease in enzyme activity was observed when compared to the control group.
- Open Access
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Medication-related readmissions in an acute care setting: A retrospective study at a tertiary hospital, Oman
Background: Hospital readmissions are a key indicator of healthcare quality, with medication-related problems (MRPs) contributing significantly to preventable readmissions. Identifying the prevalence and factors associated with medication-related readmissions can help improve patient safety and reduce healthcare burden. Objective: To assess the prevalence of medication-related readmissions within 30 days post-discharge in an acute care setting at the Royal Hospital, Oman, and identify associated risk factors. Methods: A retrospective, cross-sectional study reviewed electronic medical records of adult patients admitted to the acute medicine department between January and December 2021. Patients readmitted within 30 days were analyzed for demographic characteristics, length of stay, comorbidities, prescribed medications, and drug-related problems. Results: Of 3923 admissions, 418 (10.7%) were readmitted within 30 days post-discharge, with 46 (11%) classified as medication-related. Significant predictors of readmission included female gender ( p = 0.015), prolonged length of stay during initial admission ( p = 0.001), and infection ( p = 0.023). Drug-related problems included adverse drug reactions, inappropriate prescribing, and drug-drug interactions. Polypharmacy was common, but not significantly associated with an increased risk of readmission ( p > 0.05). Conclusion: Medication-related readmissions remain a healthcare challenge. Pharmacist-led medication reconciliation and improved prescribing practices may help reduce preventable readmissions.
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Open AccessMedication-related readmissions in an acute care setting: A retrospective study at a tertiary hospital, Oman
Background: Hospital readmissions are a key indicator of healthcare quality, with medication-related problems (MRPs) contributing significantly to preventable readmissions. Identifying the prevalence and factors associated with medication-related readmissions can help improve patient safety and reduce healthcare burden. Objective: To assess the prevalence of medication-related readmissions within 30 days post-discharge in an acute care setting at the Royal Hospital, Oman, and identify associated risk factors. Methods: A retrospective, cross-sectional study reviewed electronic medical records of adult patients admitted to the acute medicine department between January and December 2021. Patients readmitted within 30 days were analyzed for demographic characteristics, length of stay, comorbidities, prescribed medications, and drug-related problems. Results: Of 3923 admissions, 418 (10.7%) were readmitted within 30 days post-discharge, with 46 (11%) classified as medication-related. Significant predictors of readmission included female gender ( p = 0.015), prolonged length of stay during initial admission ( p = 0.001), and infection ( p = 0.023). Drug-related problems included adverse drug reactions, inappropriate prescribing, and drug-drug interactions. Polypharmacy was common, but not significantly associated with an increased risk of readmission ( p > 0.05). Conclusion: Medication-related readmissions remain a healthcare challenge. Pharmacist-led medication reconciliation and improved prescribing practices may help reduce preventable readmissions.
- Open Access
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Enhancing diabetic foot ulcer healing: The impact of honey and hydrogel on wound size and infection
Background: Complications of Diabetic Foot Ulcers (DFU) could lead to serious decisions like amputation if not properly managed. Numerous studies have focused on using honey and hydrogel for DFU to promote wound healing, tissue regeneration, reduce wound size, and minimize the risk of wound infection. This investigation aimed to estimate the impact of the specific therapy with honey and hydrogel, independently or combined, on the wound size and its link to reducing the risk of complications linked to DFU. Methods: This study was a randomized controlled clinical trial performed at the outpatient clinic at the Diabetic Foot Center, King Fahad Specialist Hospital, Al-Qassem, Saudi Arabia. The sample size was one hundred twenty adult cases of diabetic mellitus type 2 with second-degree foot ulcers, and the trial ran from February 15th, 2019, to February 15th, 2023. The registration on clinicaltrials.gov is ID: NCT 038816618. Results: Mean wound size at one week among different treatments: honey alone (mean size 0.293 cm 2 ), hydrogel alone (mean size 0.439 cm 2 ), honey and hydrogel (mean size 0.184 cm 2 ), and Fucidin ointment or cream (mean size 0.665 cm 2 ). There is a correlation between wound size and healing time. Bigger wound sizes were found to have a longer healing time ( p < 0.001). Conclusion: Diabetic foot ulcers healing through a honey and hydrogel combination reduces the wound size after two weeks. Infected wounds and neuropathy could probably retard the healing process.
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Open AccessEnhancing diabetic foot ulcer healing: The impact of honey and hydrogel on wound size and infection
Background: Complications of Diabetic Foot Ulcers (DFU) could lead to serious decisions like amputation if not properly managed. Numerous studies have focused on using honey and hydrogel for DFU to promote wound healing, tissue regeneration, reduce wound size, and minimize the risk of wound infection. This investigation aimed to estimate the impact of the specific therapy with honey and hydrogel, independently or combined, on the wound size and its link to reducing the risk of complications linked to DFU. Methods: This study was a randomized controlled clinical trial performed at the outpatient clinic at the Diabetic Foot Center, King Fahad Specialist Hospital, Al-Qassem, Saudi Arabia. The sample size was one hundred twenty adult cases of diabetic mellitus type 2 with second-degree foot ulcers, and the trial ran from February 15th, 2019, to February 15th, 2023. The registration on clinicaltrials.gov is ID: NCT 038816618. Results: Mean wound size at one week among different treatments: honey alone (mean size 0.293 cm 2 ), hydrogel alone (mean size 0.439 cm 2 ), honey and hydrogel (mean size 0.184 cm 2 ), and Fucidin ointment or cream (mean size 0.665 cm 2 ). There is a correlation between wound size and healing time. Bigger wound sizes were found to have a longer healing time ( p < 0.001). Conclusion: Diabetic foot ulcers healing through a honey and hydrogel combination reduces the wound size after two weeks. Infected wounds and neuropathy could probably retard the healing process.
- Open Access
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Assessing knowledge, awareness, and attitudes towards patient safety among health professional students in Iraq
Background: Patient safety is crucial in providing quality healthcare, and the need for patient safety regulation is acknowledged on a global level. Inadequate dedication has been given to patient safety education for healthcare professionals, resulting in a limited understanding of the nature of risk in healthcare. Objectives: This study aimed to evaluate the personal knowledge, awareness, and attitudes towards patient safety among the health professional students in Iraq, using measures applied in public and private universities with five health profession colleges (Medicine, Pharmacy, Dentistry, Nursing, and Health & Medical lab Techniques), before incorporating patient safety topics into the curriculum. Methods: A retrospective, cross-sectional study was conducted based on a survey of participants ( n = 747) using validated questions adapted from the World Health Organization questionnaire. The results were analyzed using IBM SPSS software. Results: Our data showed that the majority of participants had a medium level of knowledge and awareness about healthcare errors and patient safety. Nevertheless, our participants’ attitude was positive regarding reporting the error and learning from their mistakes. Conclusion: Reducing patient maltreatment will require long-term continuous efforts to establish effective education that can address the local difficulties and improve patient safety.
- 23 July 2026
- Published by Hamad bin Khalifa University Press (HBKU Press) in Journal of Emergency Medicine, Trauma and Acute Care
- Vol. 2026 (3)
Open AccessAssessing knowledge, awareness, and attitudes towards patient safety among health professional students in Iraq
Background: Patient safety is crucial in providing quality healthcare, and the need for patient safety regulation is acknowledged on a global level. Inadequate dedication has been given to patient safety education for healthcare professionals, resulting in a limited understanding of the nature of risk in healthcare. Objectives: This study aimed to evaluate the personal knowledge, awareness, and attitudes towards patient safety among the health professional students in Iraq, using measures applied in public and private universities with five health profession colleges (Medicine, Pharmacy, Dentistry, Nursing, and Health & Medical lab Techniques), before incorporating patient safety topics into the curriculum. Methods: A retrospective, cross-sectional study was conducted based on a survey of participants ( n = 747) using validated questions adapted from the World Health Organization questionnaire. The results were analyzed using IBM SPSS software. Results: Our data showed that the majority of participants had a medium level of knowledge and awareness about healthcare errors and patient safety. Nevertheless, our participants’ attitude was positive regarding reporting the error and learning from their mistakes. Conclusion: Reducing patient maltreatment will require long-term continuous efforts to establish effective education that can address the local difficulties and improve patient safety.
- Open Access
- 5 May 2026
- Published by MDPI AG in Journal of the Oman Medical Association
- Vol. 3 (1) , 7
Real-World Experience with Ruxolitinib in Myeloproliferative Neoplasms: A Single-Center Study from Oman
Background: Myeloproliferative neoplasms (MPNs)—including primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)—are clonal stem-cell disorders driven by JAK–STAT pathway activation within an inflammatory microenvironment. Ruxolitinib (RUX), a JAK1/2 inhibitor, improves splenomegaly and symptom burden in myelofibrosis and serves as second-line therapy in hydroxyurea-resistant/intolerant PV. However, real-world data from Middle Eastern populations remains scarce. This study evaluates the effectiveness, safety, and dosing practices of RUX in a heterogeneous Omani MPN cohort. Methods: Electronic records were reviewed for adults diagnosed with MF, PV, or ET who received RUX at Sultan Qaboos University Hospital or the National Hematology and BMT Center between 2018 and 2025. Only patients with at least six months of follow-up were included. Clinical variables, laboratory results, dosing information, and data on treatment responses and toxicities were extracted. Outcomes focused on spleen size changes, symptom improvement, hematologic responses, adverse events, and reasons for treatment discontinuation. Results: Twenty-eight patients were included (71% PMF; mean age 52.6 years). The median time from diagnosis to RUX initiation was 28 months. Among MF patients, mean spleen size decreased by 35% (p = 0.003); 28% achieved ≥35% reduction. Symptomatic improvement was reported by 60%. LDH levels remained unchanged. PV patients showed spleen control in 75% and symptom benefit in all cases, while ET responses were limited. Cytopenias (21%) and infections (11%) were the most common toxicities; discontinuation occurred in 8/28 of patients, and two patients died while on therapy. Initial dosing was frequently inappropriate, particularly underdosing in MF and overdosing in PV. Conclusions: RUX provided meaningful spleen and symptom improvement in MF and PV; however, toxicity, delayed initiation, and inconsistent dosing practices limited overall outcomes. Enhanced guideline-based dosing, proactive toxicity management, and structured multidisciplinary follow-up are essential to optimize RUX use in regional MPN practice.
- 5 May 2026
- Published by MDPI AG in Journal of the Oman Medical Association
- Vol. 3 (1) , 7
Open AccessReal-World Experience with Ruxolitinib in Myeloproliferative Neoplasms: A Single-Center Study from Oman
Background: Myeloproliferative neoplasms (MPNs)—including primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)—are clonal stem-cell disorders driven by JAK–STAT pathway activation within an inflammatory microenvironment. Ruxolitinib (RUX), a JAK1/2 inhibitor, improves splenomegaly and symptom burden in myelofibrosis and serves as second-line therapy in hydroxyurea-resistant/intolerant PV. However, real-world data from Middle Eastern populations remains scarce. This study evaluates the effectiveness, safety, and dosing practices of RUX in a heterogeneous Omani MPN cohort. Methods: Electronic records were reviewed for adults diagnosed with MF, PV, or ET who received RUX at Sultan Qaboos University Hospital or the National Hematology and BMT Center between 2018 and 2025. Only patients with at least six months of follow-up were included. Clinical variables, laboratory results, dosing information, and data on treatment responses and toxicities were extracted. Outcomes focused on spleen size changes, symptom improvement, hematologic responses, adverse events, and reasons for treatment discontinuation. Results: Twenty-eight patients were included (71% PMF; mean age 52.6 years). The median time from diagnosis to RUX initiation was 28 months. Among MF patients, mean spleen size decreased by 35% (p = 0.003); 28% achieved ≥35% reduction. Symptomatic improvement was reported by 60%. LDH levels remained unchanged. PV patients showed spleen control in 75% and symptom benefit in all cases, while ET responses were limited. Cytopenias (21%) and infections (11%) were the most common toxicities; discontinuation occurred in 8/28 of patients, and two patients died while on therapy. Initial dosing was frequently inappropriate, particularly underdosing in MF and overdosing in PV. Conclusions: RUX provided meaningful spleen and symptom improvement in MF and PV; however, toxicity, delayed initiation, and inconsistent dosing practices limited overall outcomes. Enhanced guideline-based dosing, proactive toxicity management, and structured multidisciplinary follow-up are essential to optimize RUX use in regional MPN practice.
- Open Access
- 12 March 2026
- Published by Wolters Kluwer Health in International Journal of Nutrition, Pharmacology, Neurological Diseases
- Vol. 16 (3) , 373-379
Prevalence, Risk Factors, and Management Strategies of Alopecia in Saudi Arabia: A Systematic Review
Background: Hair loss disorders, such as alopecia areata and androgenetic alopecia, are prevalent conditions that significantly impact individuals’ physical appearance and psychological well-being. Methods: We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched PubMed, Google Scholar, and Saudi journals using relevant terms. Eleven studies met the inclusion criteria. Results: Prevalence of hair loss ranged from 13.8% to 71.3%. Key risk factors included stress, vitamin D deficiency, metabolic syndrome, autoimmune disease, and COVID-19. Only 35% sought medical advice. Use of low-dose oral minoxidil was limited. Conclusion Hair loss is common in Saudi Arabia and often goes untreated. Public education, improved access to care, and future research are needed.
- 12 March 2026
- Published by Wolters Kluwer Health in International Journal of Nutrition, Pharmacology, Neurological Diseases
- Vol. 16 (3) , 373-379
Open AccessPrevalence, Risk Factors, and Management Strategies of Alopecia in Saudi Arabia: A Systematic Review
Background: Hair loss disorders, such as alopecia areata and androgenetic alopecia, are prevalent conditions that significantly impact individuals’ physical appearance and psychological well-being. Methods: We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched PubMed, Google Scholar, and Saudi journals using relevant terms. Eleven studies met the inclusion criteria. Results: Prevalence of hair loss ranged from 13.8% to 71.3%. Key risk factors included stress, vitamin D deficiency, metabolic syndrome, autoimmune disease, and COVID-19. Only 35% sought medical advice. Use of low-dose oral minoxidil was limited. Conclusion Hair loss is common in Saudi Arabia and often goes untreated. Public education, improved access to care, and future research are needed.
- 15 October 2025
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 43 (Sup1) , 63-66
The importance of iron and folic acid supplementation in pregnancy and strategies to improve outcomes
Background: Iron and folic acid are essential micronutrients for reproductive health. While supplementation is common during pregnancy, excessive intake may disrupt hormonal balance and impair fertility. Aim: To evaluate the effects of iron and folic acid supplementation and overdose on fertility and reproductive hormone levels in female mice. Methodology: An experimental study was conducted on 36 female mice divided into six groups receiving different doses of folic acid, iron, or combinations of both for seven days. Reproductive hormone levels were measured, and pregnancy and fertility rates were assessed. Data were analyzed using ANOVA and chi-square tests. Results: Iron-treated mice showed a significant reduction in luteinizing hormone and follicle-stimulating hormone levels (p<0.001) and no pregnancies occurred in these groups. Low-dose folic acid improved pregnancy and fertility rates compared to high-dose folic acid (p=0.034). Conclusion: High-dose iron causes infertility in female mice by disrupting hormonal balance, while normal doses of folic acid enhance fertility. These findings highlight the need for cautious micronutrient supplementation and medical supervision during pregnancy.
- 15 October 2025
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 43 (Sup1) , 63-66
The importance of iron and folic acid supplementation in pregnancy and strategies to improve outcomes
Background: Iron and folic acid are essential micronutrients for reproductive health. While supplementation is common during pregnancy, excessive intake may disrupt hormonal balance and impair fertility. Aim: To evaluate the effects of iron and folic acid supplementation and overdose on fertility and reproductive hormone levels in female mice. Methodology: An experimental study was conducted on 36 female mice divided into six groups receiving different doses of folic acid, iron, or combinations of both for seven days. Reproductive hormone levels were measured, and pregnancy and fertility rates were assessed. Data were analyzed using ANOVA and chi-square tests. Results: Iron-treated mice showed a significant reduction in luteinizing hormone and follicle-stimulating hormone levels (p<0.001) and no pregnancies occurred in these groups. Low-dose folic acid improved pregnancy and fertility rates compared to high-dose folic acid (p=0.034). Conclusion: High-dose iron causes infertility in female mice by disrupting hormonal balance, while normal doses of folic acid enhance fertility. These findings highlight the need for cautious micronutrient supplementation and medical supervision during pregnancy.
- 15 October 2025
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 43 (Sup1) , 59-62
Impact of dapagliflozin on weight and BMI in Omani patients with type 2 diabetes: a strategy for enhancing metabolic health
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) work by inhibiting glucose reabsorption in the kidneys' proximal tubules. This process helps lower plasma glucose levels, reduce body weight, and decrease cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). Aim: This study evaluates the impact of dapagli¬flozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, on body weight and BMI in Omani patients with type 2 diabetes mellitus (T2DM). Methodology: A retrospective pre-post cohort study was conducted at Diwan Polyclinic, Muscat, enrolling 124 T2DM patients between January 2020 and December 2022. Patients who used dapagliflozin for at least 24 months were included. Medical records were analyzed for weight and BMI changes. Statistical analyses included paired t-tests, two-way ANOVA, and chi-square tests to assess differences across gender and treatment regimens. Results: The mean age of participants was 61 years, with 50.8% being female. At baseline, 47.6% were obese, with an average BMI of 30.49 kg/m². After two years of dapagliflozin treatment, patients experienced significant weight loss (-3.43 kg, 4.45% reduction) and a decrease in BMI to 28.78 kg/m². Females showed greater weight loss (-4.13 kg) than males (-2.77 kg). Weight reduction was independent of treatment regimens. Conclusion: Dapagliflozin effectively reduces weight and BMI in T2DM patients, improving metabolic health. Further research is needed to explore long-term outcomes and contributing mechanisms.
- 15 October 2025
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 43 (Sup1) , 59-62
Impact of dapagliflozin on weight and BMI in Omani patients with type 2 diabetes: a strategy for enhancing metabolic health
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) work by inhibiting glucose reabsorption in the kidneys' proximal tubules. This process helps lower plasma glucose levels, reduce body weight, and decrease cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). Aim: This study evaluates the impact of dapagli¬flozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, on body weight and BMI in Omani patients with type 2 diabetes mellitus (T2DM). Methodology: A retrospective pre-post cohort study was conducted at Diwan Polyclinic, Muscat, enrolling 124 T2DM patients between January 2020 and December 2022. Patients who used dapagliflozin for at least 24 months were included. Medical records were analyzed for weight and BMI changes. Statistical analyses included paired t-tests, two-way ANOVA, and chi-square tests to assess differences across gender and treatment regimens. Results: The mean age of participants was 61 years, with 50.8% being female. At baseline, 47.6% were obese, with an average BMI of 30.49 kg/m². After two years of dapagliflozin treatment, patients experienced significant weight loss (-3.43 kg, 4.45% reduction) and a decrease in BMI to 28.78 kg/m². Females showed greater weight loss (-4.13 kg) than males (-2.77 kg). Weight reduction was independent of treatment regimens. Conclusion: Dapagliflozin effectively reduces weight and BMI in T2DM patients, improving metabolic health. Further research is needed to explore long-term outcomes and contributing mechanisms.
- 15 October 2025
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 43 (Sup1) , 75-77
Utilization patterns, cost analysis, and monitoring burden of warfarin and rivaroxaban in Oman: a retrospective study (2019–2024)
Background: Warfarin and Rivaroxaban are common anticoagulants with distinct profiles. Warfarin, a vitamin K an¬tagonist, requires frequent international normalized ratio (INR) monitoring and dose adjustments. Rivaroxaban, a di¬rect oral anticoagulant (DOAC), allows fixed dosing with minimal monitoring but is more expensive. Aim: To compare prescribing trends, patient demographics, and cost implications of warfarin and rivaroxaban in Oman from January 2019 to May 2024. Methodology: Prescription data were reviewed for drug utilization, number of patients, prescrip¬tions, tablets dispensed, and related costs. INR test counts for warfarin were also analyzed. Costs were reported in Omani Rial (R.O). Results: Warfarin was prescribed to 238 patients, totaling 6,813 prescriptions and 292,812 tablets. Rivaroxaban was prescribed to 28 patients, with 445 prescriptions and 11,491 tablets. Total cost: warfarin (12,143.28 R.O), rivaroxaban (7,554.38 R.O). Switching all warfarin users to rivaroxaban would cost 30,184.56 R.O. INR moni¬toring for warfarin users involved 1,626 tests. Conclusion: Warfarin remains widely used in Oman due to lower cost, despite rivaroxaban’s ease of use. High expense limits rivaroxaban adoption. Future studies should explore long-term outcomes and cost-effectiveness of broader DOAC use.
- 15 October 2025
- Published by PHARMAKON-PRESS in Epitheorese Klinikes Farmakologias kai Farmakokinetikes – Greek Edition
- Vol. 43 (Sup1) , 75-77
Utilization patterns, cost analysis, and monitoring burden of warfarin and rivaroxaban in Oman: a retrospective study (2019–2024)
Background: Warfarin and Rivaroxaban are common anticoagulants with distinct profiles. Warfarin, a vitamin K an¬tagonist, requires frequent international normalized ratio (INR) monitoring and dose adjustments. Rivaroxaban, a di¬rect oral anticoagulant (DOAC), allows fixed dosing with minimal monitoring but is more expensive. Aim: To compare prescribing trends, patient demographics, and cost implications of warfarin and rivaroxaban in Oman from January 2019 to May 2024. Methodology: Prescription data were reviewed for drug utilization, number of patients, prescrip¬tions, tablets dispensed, and related costs. INR test counts for warfarin were also analyzed. Costs were reported in Omani Rial (R.O). Results: Warfarin was prescribed to 238 patients, totaling 6,813 prescriptions and 292,812 tablets. Rivaroxaban was prescribed to 28 patients, with 445 prescriptions and 11,491 tablets. Total cost: warfarin (12,143.28 R.O), rivaroxaban (7,554.38 R.O). Switching all warfarin users to rivaroxaban would cost 30,184.56 R.O. INR moni¬toring for warfarin users involved 1,626 tests. Conclusion: Warfarin remains widely used in Oman due to lower cost, despite rivaroxaban’s ease of use. High expense limits rivaroxaban adoption. Future studies should explore long-term outcomes and cost-effectiveness of broader DOAC use.